Alpha Teknova, Inc.

NASDAQ:TKNO

Drug Manufacturers - Specialty & Generic

Healthcare
$7.88 +4.55%

+$0.23 today

Market cap
$495.68M
Beta
0.63
P/E (TTM)
-16.2
EPS (TTM)
-$0.32
52W Low $1.91High $6.68

Volume 0.30M

Average 0.13M

TKNO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Alpha Teknova, Inc.NASDAQ: TKNO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $695K fell 18.4% year over year, behind the +1.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 10.6% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Stock-based compensation amounted to 8.5% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -18.4% toward the trailing-twelve-month pace of +1.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$695K-10.6% QoQ
Last fiscal yearDec 2025
$3.43M-6.5% YoY
LTMMar 2026
$2.42M+1.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.4%——
1 year-6.5%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.43M USD
Year-over-year change
-6.5%
4-year CAGR
+21.9%

Stock-Based Compensation vs competitors

How TKNO compares with its peers on the latest reported figures

  • TKNO's LTM Mar 2026 stock-based compensation of $2.42M is the 7th largest of the 8 companies compared; the peer median is $26M.
  • Its year-over-year change of +1.9% is the 2nd highest of 8, against a peer median of -26.1%.
  • Stock-based compensation amounts to 5.8% of revenue for TKNO, versus a peer median of 4.2%.
TKNO Competitors Peer median
Stock-Based Compensation for TKNO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TECHBio-Techne CorporationLTM Sep 2026$43.09M +56.0%+1.8%3.5%
RGENRepligen CorporationLTM Jun 2026$33.29M -26.1%+6.1%4.2%
LABStandard BioTools Inc.LTM Mar 2026$27.48M -5.7%+25.8%31.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$26M -36.2%—12.5%
BLFSBioLife Solutions, Inc.LTM Mar 2026$23.65M -18.2%-3.2%23.7%
AZTAAzenta, Inc.LTM Sep 2026$12.24M -41.4%+9.3%2.0%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.42M +1.9%-2.6%5.8%
MLABMesa Laboratories, Inc.LTM Mar 2026$0 -100.0%+12.5%0.0%
Peer median (excluding TKNO) $26M-26.1%+7.7%4.2%

Competitors are the stored peer set for TKNO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.8M)(47.47M)(36.78M)(26.75M)(17.26M)
Depreciation & Amortization2.88M3.17M5.66M6.58M6.34M
Deferred Income Tax(2.84M)(1.93M)(304K)(92K)52K
Stock-Based Compensation1.55M3.71M4.14M3.67M3.43M
Change in Working Capital(1.77M)(7.33M)2.25M(873K)(2.68M)
Accounts Receivables(49K)380K314K(494K)(374K)
Inventory(2.25M)(7.55M)330K244K(2.37M)
Accounts Payables270K572K(773K)(594K)470K
Other Working Capital263K(736K)2.38M(29K)(407K)
Other Non-Cash Items906K22.46M6.22M5.08M1.47M
Operating Cash Flow(9.07M)(27.4M)(18.81M)(12.39M)(8.65M)
Capital Expenditures(19.88M)(28.15M)(7.93M)(1.13M)(1.15M)
Acquisitions (Net)00000
Purchases of Investments000(30.28M)(17.15M)
Sales of Investments1.83M004M29M
Other Investing Activities529K0197K125K0
Investing Cash Flow(17.52M)(28.15M)(7.74M)(27.28M)10.7M
Debt Repayment11.89M10.14M(10M)01.11M
Common Stock Issued102.67M439K22.5M15.1M211K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.77M)(307K)(32K)(214K)(1.17M)
Financing Cash Flow110.79M10.27M12.8M14.89M151K
Effect of Forex Changes00000
Net Change in Cash84.2M(45.28M)(13.75M)(24.78M)2.2M
Free Cash Flow(28.95M)(55.55M)(26.75M)(13.52M)(9.79M)

Alpha Teknova, Inc.

NASDAQ:TKNO

Intrinsic Alpha fair value

Locked

Current Price

$7.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.